| |
Dose-escalation cohort
|
Dose-expansion cohort (ALK-positive)
|
Both cohorts
|
|---|
|
Total (n = 30)a
|
525 mg (n = 16)b
|
Total (n = 46)
|
|---|
|
Overall
|
20 (67)
|
15 (94)
|
35 (76)
|
|
Nausea
|
7 (23)
|
10 (63)
|
17 (37)
|
|
Vomiting
|
6 (20)
|
10 (63)
|
16 (35)
|
|
Fatigue
|
13 (43)
|
3 (19)
|
16 (35)
|
|
Decreased appetite
|
1 (3)
|
4 (25)
|
5 (11)
|
|
Diarrhea
|
3 (10)
|
2 (13)
|
5 (11)
|
|
Rash
|
0
|
3 (19)
|
3 (7)
|
|
Headache
|
1 (33)
|
2 (13)
|
3 (7)
|
|
Constipation
|
2 (7)
|
1 (6)
|
3 (7)
|
|
Peripheral neuropathy
|
0
|
2 (13)
|
2 (4)
|
|
Cataract nuclear
|
0
|
2 (13)
|
2 (4)
|
|
Periorbital edema
|
0
|
2 (13)
|
2 (4)
|
|
Blurred vision
|
0
|
2 (13)
|
2 (4)
|
|
Anemia
|
2 (7)
|
0
|
2 (4)
|
|
Increased blood creatinine
|
2 (7)
|
0
|
2 (4)
|
-
ALK anaplastic lymphoma kinase
-
aExcludes 3 ALK-positive patients
-
bIncludes 3 ALK-positive patients from the dose-escalation cohort
